Then, we tuned the aggregated parameters using the biological constrains, described in Material and Methods, combined with the experimental values of breast cancer volumes and the proportion of CSCs derived from the percentage of Sca-1+ and CD44+/CD24− cells. This evidence concerns the gene CD44 and breast cancer.